NASDAQ:MBII

Marrone Bio Innovations - MBII Stock Forecast, Price & News

$0.80

0.00 (0.00%)

(As of 09/7/2022)

Add

Compare

Today's Range: $0.80
▼
$0.80
50-Day Range: $0.80
▼
$0.80
52-Week Range: $0.55
▼
$1.55

Volume: 38 shs
Average Volume: 919,497 shs
Market Capitalization: $145.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.90

Marrone Bio Innovations MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 138.1% Upside
$1.90 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -11.74
Upright™ Environmental Score
News Sentiment: 0.12
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.06) to ($0.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Basic Materials Sector

151st out of 167 stocks

Agricultural Chemicals Industry

9th out of 10 stocks

3.3

Analyst's Opinion

Consensus Rating
Marrone Bio Innovations has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.90, Marrone Bio Innovations has a forecasted upside of 138.1% from its current price of $0.80.
Amount of Analyst Coverage
Marrone Bio Innovations has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for MBII.

0.0

Dividend Strength

Dividend Yield
Marrone Bio Innovations does not currently pay a dividend.
Dividend Growth
Marrone Bio Innovations does not have a long track record of dividend growth.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Marrone Bio Innovations has received a -77.58% net impact score from Upright. The largest negative impact of Marrone Bio Innovations in category "Biodiversity" seems to be driven mostly by its "Seed treatments", "Synthetic herbicides", and "Synthetic fungicides" products. See details.
Environmental Sustainability
The Environmental Impact score for Marrone Bio Innovations is -11.74.

1.7

News and Social Media Coverage

News Sentiment
Marrone Bio Innovations has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.30 average news sentiment score of Basic Materials companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Marrone Bio Innovations this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Marrone Bio Innovations insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Marrone Bio Innovations is held by insiders.
Percentage Held by Institutions
68.42% of the stock of Marrone Bio Innovations is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Marrone Bio Innovations are expected to grow in the coming year, from ($0.06) to ($0.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Marrone Bio Innovations is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Marrone Bio Innovations is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Marrone Bio Innovations has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Marrone Bio Innovations (NASDAQ:MBII) Stock

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Stock News Headlines

September 28, 2022 | msn.com

MBI: Body found in Forrest Co. identified

September 28, 2022 | benzinga.com

The agriculture microbial market is projected to reach US$ 18,003.75 million by 2028 from US$ 6,901.93 million in 2021

September 28, 2022 | marketwatch.com

Crop Protection Chemicals Market Size to Grow at 4.35% CAGR During the Forecast Period of 2022-2027 | 125 Report Pages

September 26, 2022 | americanbankingnews.com

Marrone Bio Innovations (NASDAQ:MBII) Earns Sell Rating from Analysts at StockNews.com

September 25, 2022 | finance.yahoo.com

Conceptual Innovations' HaloDrive delivers precision and maneuverability while carrying heavy loads

July 13, 2022 | finance.yahoo.com

Marrone name goes away in sale to Bioceres

June 27, 2022 | apnews.com

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GRRB, MBII, EMCF, MN

June 16, 2022 | finance.yahoo.com

BIOX: Bioceres Crop Solutions Granted Approval by China to Import HB4 Soy for Food & Feed. HB4 Soy & HB4 Wheat expected to generate incremental EBITDA between $35 million and $45 million in fiscal 2025.

June 3, 2022 | finance.yahoo.com

AgStart seeks support to expand critical startup lab space in Woodland

May 17, 2022 | finance.yahoo.com

Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1

May 11, 2022 | seekingalpha.com

Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q1 2022 Results - Earnings Call Transcript

May 11, 2022 | finance.yahoo.com

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results

May 11, 2022 | finance.yahoo.com

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates

May 9, 2022 | ca.proactiveinvestors.com

Water Tower Research publishes report on pending merger between Marrone Bio and Bioceres Crop Solutions

April 29, 2022 | markets.businessinsider.com

Mid-Afternoon Market Update: Nasdaq Down 3%; Accolade Shares Slide

April 27, 2022 | finance.yahoo.com

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time

April 11, 2022 | finance.yahoo.com

Former Marrone Bio executive Absi sentenced to two years in prison

March 29, 2022 | finance.yahoo.com

Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates

March 28, 2022 | finance.yahoo.com

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

March 25, 2022 | benzinga.com

Preview: Marrone Bio Innovations's Earnings

March 18, 2022 | marketwatch.com

Bioceres, Marrone Bio Innovations To Combine Companies in All-Stock Transaction

March 18, 2022 | marketwatch.com

Marrone Bio Innovations Shares Rise 25% on Bioceres All-Stock Transaction

March 17, 2022 | finanznachrichten.de

Marrone Bio Innovations: Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement

March 17, 2022 | marketwatch.com

Bioceres Crop Shares Drop 15% After Bid to Buy Marrone Bio

March 16, 2022 | finance.yahoo.com

Marrone Bio to sell for $236 million to Argentinian company Bioceres

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Company Calendar

Last Earnings: 11/10/2021
Today: 10/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Agricultural chemicals
Sub-Industry: N/A
Sector: Basic Materials
Current Symbol: NASDAQ:MBII
CUSIP: N/A
CIK: 1441693
Web: www.marronebioinnovations.com
Phone: (530) 750-2800
Fax: N/A
Employees: 153
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.90
High Stock Price Forecast: $2.50
Low Stock Price Forecast: $1.30
Forecasted Upside/Downside: +138.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,550,000.00
Net Margins: -47.07%
Pretax Margin: -47.12%
Return on Equity: -70.87%
Return on Assets: -25.23%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 0.79
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $44.31 million
Price / Sales: 3.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 4.69

Miscellaneous

Outstanding Shares: 182,378,000
Free Float: 173,259,000
Market Cap: $145.56 million
Optionable: Not Optionable
Beta: 0.36

Key Executives

Mr. Kevin R. Helash (Age 57)
CEO & Director
Comp: $416.64k

Dr. Pamela G. Marrone Ph.D. (Age 65)
Founder, Advisor & Non-Employee Director
Comp: $254.58k

Ms. Linda V. Moore (Age 75)
Chief Compliance Officer, Chief Legal Officer & Sec.
Comp: $316.74k

Mr. LaDon Johnson CPA
CPA, Interim Chief Financial Officer

Dr. Amit Vasavada Ph.D. (Age 67)
Sr. VP of Research Devel. & Chief Technical Officer

Andre Trepanier
Director of Marketing

Mr. Barner Jones
Director of National Sales & Account Management

Mr. Matti Tiainen (Age 33)
Sr. VP of International Sales

Mr. Keith J. Pitts (Age 58)
Sr. VP of Regulatory & Gov. Affairs and Chief Sustainability Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MBII Stock - Frequently Asked Questions

Should I buy or sell Marrone Bio Innovations stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBII shares.
View MBII analyst ratings or view top-rated stocks.
What is Marrone Bio Innovations' stock price forecast for 2022?: 2 brokers have issued 12 month price objectives for Marrone Bio Innovations' stock. Their MBII share price forecasts range from $1.30 to $2.50. On average, they predict the company's share price to reach $1.90 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts price targets for MBII or view top-rated stocks among Wall Street analysts.
How have MBII shares performed in 2022?: Marrone Bio Innovations' stock was trading at $0.7202 at the beginning of 2022. Since then, MBII stock has increased by 10.8% and is now trading at $0.7981.
View the best growth stocks for 2022 here.
How were Marrone Bio Innovations' earnings last quarter?: Marrone Bio Innovations, Inc. (NASDAQ:MBII) posted its earnings results on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The basic materials company earned $9.86 million during the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 70.87% and a negative net margin of 47.07%. During the same quarter in the previous year, the business earned ($0.04) earnings per share.

What other stocks do shareholders of Marrone Bio Innovations own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), OrganiGram (OGI), Aeterna Zentaris (AEZS).
What is Marrone Bio Innovations' stock symbol?: Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."
How do I buy shares of Marrone Bio Innovations?: Shares of MBII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Marrone Bio Innovations' stock price today?: One share of MBII stock can currently be purchased for approximately $0.80.
How much money does Marrone Bio Innovations make?: Marrone Bio Innovations (NASDAQ:MBII) has a market capitalization of $145.56 million and generates $44.31 million in revenue each year. The basic materials company earns $-16,550,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.
How many employees does Marrone Bio Innovations have?: The company employs 153 workers across the globe.
How can I contact Marrone Bio Innovations?: Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The official website for the company is www.marronebioinnovations.com. The basic materials company can be reached via phone at (530) 750-2800 or via email at ir@marronebio.com.

This page (NASDAQ:MBII) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Marrone Bio Innovations - MBII Stock Forecast, Price & News

Marrone Bio Innovations MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Marrone Bio Innovations (NASDAQ:MBII) Stock

MBII Stock News Headlines

MBII Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MBII Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™